Positions

Selected Publications

Academic Article

Year Title Altmetric
2022 Altered mental status as a presentation of rhabdomyolysis in a patient with sickle cell anemia.  Pediatric Blood and Cancer.  69. 2022
2022 COVID-19 in Children with Cancer.  Current Oncology Reports.  24:295-302. 2022
2022 How can we create resilient research systems in a pandemic?.  Cancer.  128:651-653. 2022
2022 The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question.  Blood Advances.  6:679-685. 2022
2022 Expenditures in Young Adults with Hodgkin Lymphoma: NCI-Designated Comprehensive Cancer Centers versus Other Sites.  Cancer Epidemiology, Biomarkers and Prevention.  31:142-149. 2022
2021 SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities.  Journal of Clinical Oncology.  39:3778-3788. 2021
2021 Adherence to cardiomyopathy screening guidelines among adolescent and young adult cancer survivors exposed to chest radiation and/or anthracyclines.  Journal of Cancer Survivorship.  15:738-747. 2021
2021 The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question.  Pediatric Blood and Cancer.  68. 2021
2021 Risk, Racial Disparity, and Outcomes among Patients with Cancer and COVID-19 Infection.  JAMA Oncology.  7:1064-1065. 2021
2021 Expenditures among young adults with acute lymphoblastic leukemia by site of care.  Cancer.  127:1901-1911. 2021
2021 Poverty and Survival in Childhood Cancer: A Framework to Move Toward Systemic Change 2021
2020 Preventive health service use among survivors of adolescent and young adult cancer.  Preventive Medicine Reports.  20. 2020
2020 Isolation of DNA-free RNA from human bone marrow mononuclear cells: Comparison of laboratory methods 2020
2019 Lung cancer in nonelderly patients: Facility and patient characteristics associated with not receiving treatment.  Journal of the National Comprehensive Cancer Network : JNCCN.  17:931-939. 2019
2018 Causes of inferior outcome in adolescents and young adults with acute lymphoblastic leukemia: Across oncology services and regardless of clinical trial enrollment.  Cancer Epidemiology, Biomarkers and Prevention.  27:1133-1141. 2018
2017 T-cell prolymphocytic leukemia in an adolescent with ataxiatelangiectasia: Novel approach with a JAK3 inhibitor (tofacitinib).  Blood Advances.  1:2724-2728. 2017
2017 Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma.  Leukemia.  31:1450-1453. 2017
2017 Publication outcomes of abstracts from the American Society of Hematology Annual Meeting.  American Journal of Hematology.  92:E81-E83. 2017
2017 Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: Impact of care at specialized cancer centers on survival outcome.  Cancer Epidemiology, Biomarkers and Prevention.  26:312-320. 2017
2016 Value, access, and cost of cancer care delivery at academic cancer centers.  Journal of the National Comprehensive Cancer Network : JNCCN.  14:837-847. 2016
2015 Impact of tailored education on awareness of personal risk for therapy-related complications among childhood cancer survivors.  Journal of Clinical Oncology.  33:3887-3893. 2015
2015 Impact of care at comprehensive cancer centers on outcome: Results from a population-based study.  Cancer.  121:3885-3893. 2015
2015 Long-term pulmonary function in survivors of childhood cancer.  Journal of Clinical Oncology.  33:1592-1600. 2015
2015 Piecing together the puzzle of disparities in adolescents and young adults.  Cancer.  121:1168-1171. 2015
2014 Impact of care at NCI Comprehensive Cancer Centers (NCICCC) on cancer outcome: Results from a population-based study..  Journal of Clinical Oncology.  32:188. 2014
2014 Impact of treatment site in adolescents and young adults with central nervous system tumors 2014
2013 Pitfalls of using administrative data sets to describe clinical outcomes in sickle cell disease.  Pediatric Blood and Cancer.  60:1936-1939. 2013
2013 Relapse after treatment of pediatric hodgkin lymphoma: Outcome and role of surveillance after end of therapy.  Pediatric Blood and Cancer.  60:1458-1463. 2013
2013 Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens..  British Journal of Haematology.  162:376-382. 2013
2012 Sickle cell disease in California: Sociodemographic predictors of emergency department utilization.  Pediatric Blood and Cancer.  58:66-73. 2012
2011 Sickle-cell disease in California: A population-based description of emergency department utilization.  Pediatric Blood and Cancer.  56:413-419. 2011
2010 Health care reform 2010: Expected favorable impact on childhood cancer patients and survivors.  Cancer Journal.  16:554-562. 2010

Chapter

Year Title Altmetric
2017 Making Ends Meet: Financial Issues from the Perspectives of Patients and Their Health-Care Team.  667-685. 2017

Principal Investigator On

  • A Comprehensive Investigation of Outcome Disparities in Children, Adolescents and Young Adults with Cancer  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • Adolescents and Young Adults with Cancer: Race, Ethnicity & Treatment Site  awarded by St. Baldrick's Foundation
  • CHOP NCORP - COG Study Chair  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CHOP NCORP - COG Study Chair  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CHOP NCORP - COG Study Chair  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Cancer Care Delivery Study Chair  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Continuation of Tyrosine Kinase Inhibitors after Chemotherapy in Pediatric Ph+ ALL: A Multi-site Retrospective Study  awarded by Stanford University
  • Follow-Up Care and Preventive Service Use Among Survivors of Adolescent and Young Adult Cancer  awarded by Kaiser Permanente
  • PediCARE  awarded by DANA-FARBER CANCER INSTITUTE INC
  • Pediatric Oncology COVID Cancer Case Report - A National Registry of Children with Cancer (POCC)  awarded by Concern Foundation
  • Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescents and Young Adults with Acute Lymphoblastic Leukemia  awarded by National Cancer Institute/NIH/DHHS
  • Understanding Causes of Outcome Disparities in Adolescents and Young Adults with Acute Lymphoblastic Leukemia  awarded by HYUNDAI HOPE ON WHEELS
  • Understanding Outcome Disparities in AYA with ALL  awarded by RALLY FOUNDATION
  • Understanding Outcome Disparities in AYA with ALL  awarded by RALLY FOUNDATION
  • Understanding Outcome Disparities in AYA with ALL  awarded by RALLY FOUNDATION

    • Investigator On

  • A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia, Study ITCC-054/COG AAML1921  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467,NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML1831A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations”  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS
  • ADVL1712: A Phase I Trial of Pevonedistat Given in Combination with Fludarabine, Cytarabine, and Azacitidine in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ALTE1631, A Randomized Web-Based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • APEC1621I -NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Developing a Network to Utilize Administrative and Clinical Data for Childhood, Adolescent and Young Adult Oncology Survivorship Research  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Hyundai Hope on Wheels Impact Grant  awarded by HYUNDAI HOPE ON WHEELS
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee
  • PEPCTN1812 - A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • PER CASE REIMBURSEMENT NCORP Operations Grant 7UG1CA189955 -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP
  • Reduced Burden Of Oncology Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents, and Young Adults with CD20+ Mature B-Cell Lymphoma  awarded by NEW YORK MEDICAL COLLEGE
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Workload Intensity NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)

    • Education And Training

  • MassGeneral Hospital for Children, Internship
  • Masachusetts General Hospital, Residency
  • Children's Hospital Los Angeles, Postdoctoral Fellowship
  • Doctor of Medicine, University of Florida 2002

    • Full Name

  • Julie Wolfson-Stockman